BioNexus Gene Lab Corp. announced on August 1, 2023, Mr. Liong Tai Tan, the Chief Operating Officer and a member of the Board of Directors, notified Bionexus Gene Lab Corp. (the Company) of his desire to resign from his position at the Company.

The Company and Mr. Liong Tai Tan agreed that the resignations would be effective August 31, 2023. Mr. Liong Tai Tan?s resignation is not due to any disagreement with the Company, the Company's management or the Board on any matter relating to the Company?s operations, policies, or practices (financial or otherwise), Mr. Liong Tai Tan informed the Company that he is leaving the Company and the Board of Directors to pursue other commitments. On August 2, 2023, the Board of Directors of the Company approved the appointment of Mr. Lee Su-Leng Tan as the Chief Operating Officer and not a director, effective September 1, 2023.

Mr. Tan, aged 40, has over 20 years of extensive experience in industries including Information Systems, Hospitality, Investment Management, Construction, Property Development, Travel, Government Liaison, and Life Sciences, primarily focused on commercialization, finance, and general management. From 2022 to August 2023, Mr. Tan worked as the Chief Commercial Officer for Dryox Health Limited, a startup focused on repurposing drugs for unmet needs in the dermatological space, specifically anticholinergic drugs. From 2017 to August 2023, Mr. Tan worked as the FLO Life Sciences Group?s owner and the Managing Director at Biotechnology Group, focusing on infectious diseases and oncology pre-clinical drug candidates and clinical research.

From 2018 to 2019, Mr. Tan was the President of Avillion Berhad, a publicly listed travel and hospitality group with hotels, commercial property, and inbound/outbound travel services.